ReviewLab on a chip2026
Microfluidic diffusional sizing in bioanalysis and biosensing.
Review in Lab on a chip, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microfluidic diffusional sizing (MDS) has emerged as a versatile lab-on-a-chip technology for quantitative analysis of biomolecules in solution, particularly for determining particle sizes and characterizing biomolecular interactions. By measuring the diffusive behavior of molecules under laminar flow in a microfluidic chip, MDS enables the precise determination of hydrodynamic radii and binding affinities, even in complex biological samples, while requiring only minute sample volumes. As a result, MDS is establishing itself as a key tool in the life sciences. This review summarizes recent advances and applications of MDS in the context of bioanalysis and biosensing. We outline the fundamental principles of MDS and highlight its wide range of applications, including studies of protein aggregation, antibody affinity profiling, protein-lipid interactions, and nanoparticle sizing. We further discuss recent technological developments, such as single-molecule detection, label-free strategies, and multidimensional analysis, that have significantly expanded the scope, sensitivity, and utility of MDS. We conclude with an outlook on the anticipated impact of MDS on biomedical research, diagnostics, and therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.